Biocardia Stock Analysis

Biocardia Stock Analysis Notes

About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.03. Biocardia last dividend was issued on the 6th of June 2019. The entity had 1:15 split on the 30th of May 2024. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on Biocardia please contact Peter Altman at 650 226 0120 or go to https://www.biocardia.com.

Biocardia Investment Alerts

Biocardia Upcoming and Recent Events

Biocardia Largest EPS Surprises

View All Earnings Estimates

Biocardia Environmental, Social, and Governance (ESG) Scores

Biocardia Thematic Classifications

Biocardia Stock Institutional Investors

Note, although Biocardia's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biocardia Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.64 M.

Biocardia Profitablity

Management Efficiency

Biocardia has return on total asset (ROA) of (1.1593) % which means that it has lost $1.1593 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0362) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biocardia's Return On Capital Employed is projected to increase significantly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 6.82, whereas Return On Tangible Assets are projected to grow to (4.23). At present, Biocardia's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 436.7 K, whereas Total Assets are forecasted to decline to about 3.3 M.

Technical Drivers

As of the 31st of January, Biocardia shows the Mean Deviation of 3.86, downside deviation of 5.2, and Risk Adjusted Performance of 0.0213. Biocardia technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Biocardia Price Movement Analysis

Biocardia Insider Trading Activities

Biocardia Outstanding Bonds

Biocardia Predictive Daily Indicators

Biocardia Corporate Filings

Biocardia Forecast Models

Biocardia's time-series forecasting models are one of many Biocardia's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biocardia's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biocardia prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biocardia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Biocardia. By using and applying Biocardia Stock analysis, traders can create a robust methodology for identifying Biocardia entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biocardia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biocardia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Biocardia stock analysis indicators help investors evaluate how Biocardia stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biocardia shares will generate the highest return on investment. By understating and applying Biocardia stock analysis, traders can identify Biocardia position entry and exit signals to maximize returns.

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.